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Introduction
Advances in the diagnosis and treatments of non-small cell 
lung cancer have raised new important issues about patients’ 
perspectives in the decision-making process. 
For early-stage lung cancer for example, the introduction 
of stereotactic body radiotherapy (SABR) as the standard 
treatment for medically inoperable early-stage non-small 
cell lung cancer has introduced new challenge to patients 
considerate at high risk for surgery. Recent data suggest that 
in operable patients, SABR produces outcomes comparable 
to those of surgical resection (1). Understanding the 
evolution of quality of life (QoL) after surgical treatment 
for lung cancer by the surgeon may help the patient to 
participate proactively in the difficult decision-making 
process. In thoracic surgery in general, the use of QoL 
assessment has been certainly improved in the recent years (2), 
but its use in clinical practice remains underestimated. 
A recently published survey among European thoracic 
surgeons, showed a lack of standardized patient-reported 
outcomes (PROs) collection among this community 
with 88% of all surgeons currently not integrating 
these outcomes into their clinical practices (3). Marked 
discordance was also evident when asked about the type of 
instrument used to assess QoL. Among those collecting 
QoL information, a higher percentage of respondents 
(50%) used the generic QoL questionnaire, while 48.5% of 
respondents introduced the administration of the cancer or 
lung cancer-specific tool.
Giving the lack of standardized practice in our 
specialty when collecting QoL and PROs information, 
this review aims to give an overview of the available and 
most commonly used QoL questionnaires in lung cancer 
surgery in order to facilitate future research and practical 
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applicability.
What and how to measure: QoL and PROs
The World Health Organization (4) defined in 1995 QoL 
as “individuals’ perceptions of their position in life in the context 
of their culture and value systems in which they live and in 
relation to their goals, expectations, standards and concerns”. 
Over the last decades however, the research area 
of QoL assessment has become more standardized 
and  methodolog ica l l y  r igorous ,  w i th  pub l i shed 
recommendations and Societal statements. The most 
recent one from the 5th EORTC Quality of Life in Cancer 
Clinical Trials Conference updated definitions have been 
agreed by experts in oncological field including researchers, 
regulators, industry representatives, patients and patient 
advocates (5). 
PROs is an umbrella term that embraces any outcome 
that is directly reported by the patient (in most cases 
via a standardized questionnaire). Health-related QoL 
is a multidimensional concept referring to the patient’s 
subjective perception of the effect of their disease and 
treatment on physical, psychological and social aspects of 
daily life. PROs are becoming implemented in most of the 
clinical and surgical trials. It is increasingly recognized that 
the collection, interpretation and reporting of PROs in 
cancer clinical trials poses particular challenges (6).
For this reason, the Setting International Standards in 
Analyzing Patient-Reported Outcomes and Quality of Life 
Endpoints Data for Cancer Clinical Trials (SISAQOL) 
Consortium has been recently created to address this issue 
and to develop standards, guidelines, and recommendations 
for the analysis of PROs data in cancer trials (7-9). 
The instruments currently used in lung cancer surgery 
are those which have been developed mostly to assess QoL 
in the oncological setting: these tools were focusing mainly 
on symptoms and functioning and their timeframes were 
linked to the weekly chemotherapy side-effect reports. No 
lung cancer surgery specific validated questionnaire has 
been developed and validated so far, diminishing the ability 
to draw definitive conclusions in our setting.
Lung cancer surgery setting
The ideal QoL questionnaire should be developed 
and validated according to strict guidelines verifying 
its reliability, validity, responsiveness to change and 
interpretability (10). 
Authors have indicated that the selection of the QoL 
questionnaire should be performed among already validated 
tools (11). Questionnaire’s characteristics to be considered 
are mostly related to the aim of the study, study population, 
measurement properties, study design issues, scoring and 
data analysis. Only a direct comparison within the same 
study/population may provide better justification for 
the selection of instrument. However, our group already 
demonstrated the issue of patient’s burden in completing 
long questionnaires with similar questions (12) as attempted 
in other oncology specialties (13,14). Recall bias cannot 
be completely ruled out and appear inherent to studies 
comparing two similar questionnaires.
Unfortunately, in our speciality the best timing to 
evaluate QoL has not been identified in previous published 
papers. The preoperative values seem to have a crucial role 
in this type of research. A reasonably long-term follow-
up (more than 1 year) after surgical intervention may be 
desirable, since the patient may be biased during the first 
months in his judgment by factors such as the postoperative 
hospital stay, especially if complications occurred or 
the possibility of being treated with additional systemic 
therapies. Indeed, a shorter follow-up in QoL assessment 
may increase the response rate reducing the drops-out in 
questionnaires returns over-time.
Quite generally, we can distinguish between two types 
of questionnaires: generic and cancer specific. We also 
introduce recent projects which have the potential to change 
the QoL collection in lung cancer trials: the EORTC lung 




The Medical Outcomes Study (MOS) Short Form 36-
item Health Survey (SF-36) has been developed in USA in 
1997 for application in a wide range of medical conditions 
and to provide also valid normative data from the general 
population in different countries (15). One of its main 
features is that it can be adopted to compare health status 
between populations and between diseases. The 36 items 
contribute to assess health across eight domains: bodily 
pain (BP), general health perceptions (GH), mental health 
(MH), physical functioning (PF), role limitations due to 
emotional health problems (RE), role limitations due to 
physical health problems (RP), social functioning (SF), and 
vitality (VT). Scores standardized to norms and weighted 
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averages are used to create summary physical component 
summary (PCS) and mental component summary (MCS) 
scores on a standard scale. All scales contribute in different 
proportions to the scoring of both PCS and MCS measures. 
In the SF36v2, all health dimension scores are standardized 
to norms by using a linear transformation of data originally 
scored on a 0–100 scale. Norm-based scores have a mean of 
50 and a standard deviation of 10. Any score <50 indicates a 
QoL below the general population mean. This feature helps 
the researchers to make a direct comparison of measures but 
most importantly to evaluate the long-term effectiveness of 
the treatment when the baseline assessment is not available. 
Several studies in thoracic surgery have used the SF-36v2 
especially for its characteristic to allow a direct comparison 
with general populations (16-20). 
Health-economic evaluation questionnaire
Euroqol-5 Dimension (EQ-5D) questionnaire
The EQ-5D is a generic measure widely used in health-
economic evaluation (21). It has been developed by the 
EuroQol Group to describe and value health across a 
wide range of diseases (22,23). It describes five single item 
dimensions: mobility, self-care, usual function status, pain 
and/or discomfort, and anxiety and/or depression. It is 
structured in only five questions and a visual analogue scale 
(VAS) evaluating the overall health status. This survey 
has been developed for self-completion by respondents 
and available in both paper and digital versions, but proxy 
versions are also available for populations in which self-
completion is not possible. It is a very short questionnaire 
which takes, according to developers, only 5 minutes to be 
completed. The original questionnaire, asked respondents 
to choose between three options/levels; level 1, representing 
no problems; level 2, reflecting small or moderate problems; 
and level 3, indicating extreme problems (or “unable to”). 
A more recent version expanded the response choices from 
three to five levels (EQ-5D-5L) to face the frequently 
reported EQ-5D’s ceiling effect (24).
The EQ-5D results can be presented as description of 
the single five dimensions or results of the EQ VAS as a 
measure of overall self-rated health status. Furthermore, it 
generates a single summary index value for health status. 
The EQ-5D summary index (index value) is derived by 
applying a formula that essentially attaches weights to 
each of the levels in each dimension, that can be compared 
according to the preferences of the general population of a 
country. 
Only recently, and mostly for cost-utility analysis, this 
questionnaire has been used in surgical lung cancer patients 
(25,26).
Cancer and lung cancer specific questionnaires
European Organization for Research and Treatment 
of Cancer Quality of Life Questionnaire-Core Module 
(EORTC QLQ-C30)
The EORTC QLQ-C30 is a 30-item cancer-specific 
instrument (27). Multi-trait scaling was used to determine 
five functional domain scales (physical, role, emotional, 
social and cognitive); additionally, one scale captures global 
QoL. Furthermore, the instrument also contains nine 
symptom scales capturing fatigue, nausea and vomiting, 
pain, dyspnoea, insomnia, appetite loss, constipation, 
diarrhoea and financial difficulties. The two scales for 
global health employ 7-point Likert scales; the other 28 
items use 4-point Likert scales ranging from “not at all” to 
“very much”. Each domain scale is transformed to a scale 
of 0–100. For the functional and global scales higher scores 
indicate a better level of functioning; for the symptom 
scales, higher scores represent more severe symptoms. This 
instrument has been extensively tested for reliability and 
validity (28,29). This questionnaire has been extensively 
used in our speciality (30-34). More recently a Summary 
Score (SumSc) has been developed from this questionnaire 
and validated in lung cancer surgical patient (35,36). The 
SumSc can avoid problems with potential type I errors that 
arise because of multiple testing when making comparisons 
based on the 15 outcomes generated by this whole survey. 
In addition, the use of the QLQ-C30 SumSc can reduce 
sample size requirements in clinical trials were QoL is a 
primary endpoint.
European Organization for Research and Treatment of 
Cancer Quality of Life Questionnaire (EORTC QLQ-
LC13)
The EORTC QLQ-C30 core questionnaire (30 items) can be 
supplemented by the lung cancer module QLQ-LC13 (37). 
The QLQ-LC13 module evaluates with 13 questions, 
typical symptoms of lung cancer such as cough, hemoptysis, 
shortness of breath, sore mouth or tongue, dysphagia, 
tingling hands or feet, hair loss and pain. The response 
scale and scoring system are the same as for the EORTC 
QLQ-C30, and the administration’s type and completion 
time-frame are similar (1-week). The use of disease-
specific questionnaires is not recommended without the 
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administration of the QLQ-C30, since the content validity 
is based upon this combination. The completion of both 
questionnaires however, is estimated to take 11–12 minutes. 
The main scales are focusing on disease-related symptoms 
and treatment-toxicity. It has been validated in 1994 and 
validated in a group of 883 lung cancer patients. It showed 
good psychometric properties: the dyspnea score, for 
example, showed a Cronbach’s alpha coefficient greater 
than 0.80 in many analysis (37). The module has been 
translated into more than 60 languages. A project updating 
this module to reflect aspects relevant in the newly available 
diagnostic and therapeutic options is underway and will be 
described in a separate section. 
Functional Assessment of Cancer Therapy-General 
Version (FACT-G) and Lung Cancer version (FACT-L)
The FACT-G is a 27-item cancer-specific instrument 
divided in four domains: physical, social, emotional, and 
functional wellbeing, and a total score (38). All the items are 
rated on a 5-point Likert scale, and are not in the format 
of questions, but statements. The FACT-G was developed 
to measure QoL in cancer patients receiving therapy. The 
FACT family of instruments follows a core plus module 
design. The FACT-L is a 10-item lung cancer-specific 
module that supplements the FACT-G resulting a 37-item 
questionnaire, and includes 5 sub-scales self-assessment tool 
developed to measure lung cancer patients’ QOL in the 
last 7 days, with each sub scale using a 0 to 4 Likert scale. 
FACT-G is scored by summing the individual scale scores, 
with higher scores indicating better QoL. There is also the 
option to calculate a Trial Outcome Index (TOI) which 
is the sum of the physical well-being (PWB), functional 
well-being (FWB), and any site-specific subscale (39). 
The FACT-L tool includes four generic cancer-specific 
domains and one lung cancer-specific subscale, and it 
has been reported to take 10 minutes to complete. These 
questionnaires are designed for patient self-administration, 
but can also be administered by interview format. The 
general subscales define PWB, social/family well-being, 
emotional well-being, and FWB. The fifth sub-scale 
describes the patient’s pulmonary functionality including 
shortness of breath, loss of weight, and chest tightness 
(40,41). Two points on the lung cancer subscale are 
considered clinically significant. A comparison with the 
EORTC QLQ-C30 has been recently published suggesting 
to use the decision tree presented (42). In lung cancer 
surgical patients, it has been less used compare to the 
extensive use in oncological setting (43-45).
Lung Cancer Symptom Scale (LCSS)
The LCSS (46) is a disease-specific measure of QoL, 
particularly used in clinical trials and contains both a patient 
and an observer section. The original LCSS was developed 
in 1985 at Memorial Sloan-Kettering Cancer Center. The 
patient form is a 9-item questionnaire which evaluates seven 
symptoms (appetite, fatigue, cough, shortness of breath, 
blood sputum, pain and general symptom burden), and two 
summary items that address functional activity and global 
QoL associated with lung cancer. This questionnaire, 
compare to the previous ones, doesn’t address toxicity of 
treatment and only minimally refers to psychological issues. 
The LCSS observer’s section assesses the same six symptoms 
excluding the general symptom burden. Conversely to the 
tools described before, it is referring to the past day and 
each item is scored on a 100-mm VAS (where 0= worst, 100= 
best), where the score is the length of the line marked by the 
patient. It has also been validated with a Numerical Rating 
Scale (NRS), with an 11-pt response category format (47). 
It takes 4–8 minutes the first time to understand the VAS, 
but less for the following administration. The observer part 
takes 2 minutes to complete. As shorter and very sensitive 
to change, it is one of the most validated measure in 
oncological setting (48). 
The future of QOL tools
The EORTC QLQ-LC29 Project
The recent advantages in the lung cancer treatment and the 
introduction of new radiotherapy techniques as targeted 
anti-cancer agents, made clear that the LC13 should be 
supplemented with new items to assess the effects and 
side-effects of the new various therapeutic options that are 
currently available to lung cancer patients (49,50). This 
project has also been endorsed by the European Society of 
Thoracic Surgeons highlighting the importance of having 
surgery-specific questions in a QoL questionnaire. The 
preparatory phases resulted in a provisional 48-item module. 
The aim of the international, cross-cultural, multicenter 
phase III study was to test this provisional module 
regarding relevance, acceptability, comprehensibility, and 
completeness. An important result of the phase III study was 
that 12 out of the 13 original LC13 items could be retained 
in the updated version. Phase I generated relevant QoL 
issues using a mix of sources including the involvement of 
108 lung cancer patients. Phase II transformed issues into 
questionnaire items. In an international multicenter study 
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(phase III), patients completed both the EORTC QLQ-C30 
and the 48-item provisional lung cancer module generated 
in phases I and II. The phase III study enrolled 200 patients 
with histologically confirmed lung cancer from 12 centers 
and generate a new LC29 questionnaire which for the first 
time contains a 5-item subscale specifically designed to 
address issues of patients who had surgery for lung cancer 
(e.g., pain, restriction in performance). An international, 
cross-cultural, multicenter phase IV study has concluded 
the recruitment and results are being published to fully 
validate the psychometric properties of the LC29 (51). 
Table 1 provides a summary of the methods and the most 
important results of the development process of the QLQ-
LC29. Table 2 depicts the items to assess symptoms related 
to thoracic surgery. This is the first validated scale to assess 
and is addresses patients who underwent thoracic surgery. 
Thus, the surgical subscale is optional and thus the QLQ-
LC29 follows a 24-plus-5-item administration mode. In any 
event, the QLQ-LC29 is the instrument of choice when 
the goal is to assess the impact of multimodal treatment 
for lung cancer that may comprise radio-chemotherapy, 
targeted therapy, immunotherapy and thoracic surgery. 
The EORTC Item Library
To face the continue evolution of cancer therapy, the 
EORTC QoL group has also created a tool with the 
primary aim of being used during the development of 
new instruments: the item library (52). It quickly became 
evident that a given module might not include problems 
and symptoms of novel treatments that were not available 
when the questionnaire was initially being developed. A 
static questionnaire might not always be sufficient to meet 
the demands of quickly evolving treatment modalities, the 
database began to shift into its new role as the Item Library, 
an integrated and dynamic tool to supplement existing 
measures with new relevant items. The Item Library is 
accessible to users from academia and industry after being 
granted of a specific permission through the website (https://
www.eortc.be/itemlibrary/).
The PROMIS project
The US-developed PROMIS® (Patient-Reported Outcomes 
Measurement Information System) is a set of person-
centered measures that evaluates and monitors physical, 
mental, and social health. PROMIS was established in 
2004 within the National Institutes of Health (NIH). 
These surveys can be tailored to any patient population 
and are based on item response theory to adapt to the 
specific symptoms of a patient. PROMIS utilizes a larger 
database with validated items to put a specific, reproducible, 
and validated score. One of its main features is that these 
modules may be easily incorporated into a web-based 
platform which can be link to most of the electronic medical 
patient records across countries, facilitating also multi-
centre studies. Measures were developed for children and 
adults, and has been translated into more than 40 languages. 
For most of the PROMIS measures, the reference 
population was the 2000 General US Census. The use of 
PROMIS surveys has also been recognized by the Center 
for Medical Technology Policy as one of most important 
patient-reported tools for cancer clinical studies (53). 
Scoring method for PROMIS domains is standardized 
to population-based distributions of scores, producing a 
mean of 50 and a standard deviation of 10, and provide a 
population-based standard for comparison of individual 
patient scores (54). In a Scopus review, has demonstrated 
that orthopedic surgeons are widely using PROMIS 
measures, demonstrating how accurately and reliably assess 
PROs in multidisciplinary surgical publications (55).
A recent published work has piloted the feasibility of 
integrating PROs into the institutional Society of Thoracic 
Surgery General Thoracic Surgery Database (STS-GTSD) 
with the use of the PROMIS platform. PROMIS tools allow 
for computer adaptive testing, efficiently achieving precise 
measurement of health status domains with few items. 
Mode of administration
In other specialties some studies have investigated 
the influence of the mode of administration of QoL 
questionnaires (paper, telephone-based, interviews, 
electronic) without finding any important effect (56,57). 
The introduction of technology has changed the completely 
this field due to widespread Internet use and the ability 
to monitor symptoms on-line and remotely. It has also 
demonstrated to have a positive effect on clinical outcomes 
(58,59). Although the electronic administration has been 
introduced in our settings (60-62), we still need to face 
the limitations that the still most lung cancer population 
is facing, being older and not always computer-literate. 
However, an important example is coming from the 
esophageal surgery: a recent study has demonstrated that 
post-operative symptom monitoring after major surgery is 
feasible and acceptable (63).
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Table 1 Development of the QLQ-LC29: phase 1 to 4 
Phase Method Results
Phase 1: Generation of 
issues
Literature review, review of questionnaires 
in the field, interviews with patients and 
health care providers
QLQ-LC13 was used in 240 clinical trials, among them 109 
RCTs. 92/109 (84%) of the RCTs addressed QoL in the abstract. 
In none of the studies major problems with the use of the QLQ-
LC13 were reported 
In addition, 25 questionnaires relating to respiratory diseases 
were reviewed
The literature review and the review of existing questionnaires 
yielded a total of 110 QoL issues to be considered in the context 
of lung cancer
108 patients and 103 health care providers from nine countries 
evaluated this list of issues regarding relevance and whether 
each of the issues should be included in the questionnaire
The analyses found 53 issues as relevant
Phase 2: Item generation 
and construction of a 
provisional questionnaire
Using the EORTC item library, 
questionnaires items were formulated 
that were compatible with the standard 
response scale (1= not at all, 2= a little, 
3= quite a bit, 4= very much)
After correcting for overlap/redundancy (also with the QLQ-C30), 
the provisional module contained 48 items
12 out of the 13 original QLQ-LC13 items were retained
The 48-item questionnaire was translated into the following (with 
English as the source language): German, Greek, Hebrew, Italian, 
Mandarin (Taiwan Chinese), Norwegian, Polish, and Spanish
Phase 3: International 




200 patients from nine regions (Cyprus, 
Germany, Israel, Italy, Norway, Spain, 
Poland, Taiwan, UK) filled in the QLQ-C30 
and the provisional updated lung cancer 
module. They rated each item regarding 
comprehensibility, acceptance, and 
relevance
29 of the 48 items met the pre-specified threshold criteria
Item selection criteria were specified in 
advance which took into account patients’ 
ratings as well as each item’s distribution 
properties, such as mean, range, floor/
ceiling effects, prevalence of 3 and 4 
responses, and missing responses
12 out of the 13 original QLQ-LC13 items were retained, and 
newly added items addressed side-effects of targeted therapy, 
immunotherapy, surgery, as well as fear of progression
Phase 4: International 
study to assess the 
psychometric properties 
of the QLQ-LC29 
523 patients from 12 regions (Belgium, 
Cyprus, Germany, Greece, Israel, Italy, 
Jordan, Norway, Spain, Poland, Taiwan, 
UK) filled in the QLQ-C30 and the 
QLQ-LC29. 195 patients filled in the 
questionnaire at a second assessment 
point
Confirmatory factor analyses is best compatible with a scale 
structure comprising five multi-item scales (coughing, shortness 
of breath, dyspnea, fear of progression, hair problems, surgery-
related symptoms) and 15 single items
The goal was to determine the scale 
structure, and to assess reliability, 
validity (known-group differences) and 
responsiveness to change
Internal consistencies of all multi-item scales ranged between 
0.73 and 0.86, and test-retest reliabilities ranged between 0.82 
and 0.97. Four of the 5 multi-item scales yielded known group 
differences when patients with lower vs. higher Karnofsky 
Performance Status were contrasted (P<0.01). Three of the 5 
multi-item scales showed responsiveness to change over time 
(P<0.05), so did 9 out of 15 single symptoms
QLQ, Quality of Life Questionnaire; RCT, randomized controlled trial; EORTC, European Organization for Research and Treatment of 
Cancer.
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Table 2 QLQ-LC29 subscale to assess symptoms related to thoracic surgery
Please answer the following questions only if you had surgery for 
lung cancer
Not at all A little Quite a bit Very much
55. Have you had pain in the area of surgery? 1 2 3 4
56. Has the area of your wound been oversensitive? 1 2 3 4
57. Have you been restricted in your performance due to the 
extent of surgery?
1 2 3 4
58. Have you had any difficulty using your arm or shoulder on the 
side of the chest operation?
1 2 3 4
59. Has your scar pain interfered with your daily activities? 1 2 3 4
© Copyright 2016 EORTC Quality of life Group. All rights reserved. Phase IV completed. This scale should be used in conjunction with the 
EORTC QLQ-C30 and with the entire QLQ-LC29. This is a copyrighted instrument. Please consult https://qol.eortc.org/questionnaires/ for 
user agreements. QLQ, Quality of Life Questionnaire; EORTC, European Organization for Research and Treatment of Cancer.
Conclusions
Advantages in surgical techniques and postoperative 
therapies have changed radically in the last decades the 
life expectancy of lung cancer survivors. The perioperative 
journey has also faced changes affecting directly the patient 
experience, so that PROs need to more adaptable to these 
changes than in the past. The development of more specific 
surgery-related questionnaires and dynamic measures may 
help the thoracic surgeons to implement future research 




Provenance and Peer Review: This article was commissioned 
by the Guest Editor (Peter J. Kneuertz) for the series 
“Patient reported Outcomes in Thoracic Surgery: A new 
Frontier” published in Journal of Thoracic Disease. The 
article has undergone external peer review.
Conflicts of Interest: All authors have completed the ICMJE 
uniform disclosure form (available at http://dx.doi.
org/10.21037/jtd.2019.12.131). The series “Patient reported 
Outcomes in Thoracic Surgery: A new Frontier” was 
commissioned by the editorial office without any funding 
or sponsorship. CP serves as an unpaid editorial board 
member of Journal of Thoracic Disease from Sep 2016 to 
Aug 2020. GV, MK and CP are members of the EORTC 
QoL group. The update of the lung cancer module and the 
Phase 4 study on the QLQ-LC29 have been funded by the 
EORTC. GV: reports personal fees from Roche, personal 
fees from Eisai, personal fees from Novartis, grants from 
Pfizer, grants from Breast Cancer NOW, grants from 
Yorkshire Cancer Research, grants from EORTC,  outside 
the submitted work. 
Ethical Statement: The authors are accountable for all 
aspects of the work in ensuring that questions related 
to the accuracy or integrity of any part of the work are 
appropriately investigated and resolved. Informed patient’s 
consent was obtained.
Open Access Statement: This is an Open Access article 
distributed in accordance with the Creative Commons 
Attribution-NonCommercial-NoDerivs 4.0 International 
License (CC BY-NC-ND 4.0), which permits the non-
commercial replication and distribution of the article with 
the strict proviso that no changes or edits are made and the 
original work is properly cited (including links to both the 
formal publication through the relevant DOI and the license). 
See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
References
1. Cornwell LD, Echeverria AE, Samuelian J, et al. Video-
assisted thoracoscopic lobectomy is associated with 
greater recurrence-free survival than stereotactic body 
radiotherapy for clinical stage I lung cancer. J Thorac 
Cardiovasc Surg 2018;155:395-402.
2. Gazala S, Pelletier JS, Storie D, et al. A systematic review 
and meta-analysis to assess patient-reported outcomes 
6899Journal of Thoracic Disease, Vol 12, No 11 November 2020
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2020;12(11):6892-6901 | http://dx.doi.org/10.21037/jtd.2019.12.131
after lung cancer surgery. ScientificWorldJournal 
2013;2013:789625.
3. Pompili C, Novoa N, Balduyck B. Clinical evaluation 
of quality of life: a survey among members of European 
Society of Thoracic Surgeons (ESTS). Interact Cardiovasc 
Thorac Surg 2015;21:415-9.
4. The World Health Organization Quality of Life 
assessment (WHOQOL): position paper from the World 
Health Organization. Soc Sci Med 1995;41:1403-9.
5. Bottomley A, Reijneveld JC, Koller M, et al. Current state 
of quality of life and patient-reported outcomes research. 
Eur J Cancer 2019;121:55-63.
6. Calvert M, Kyte D, Mercieca-Bebber R, et al. Guidelines 
for Inclusion of Patient-Reported Outcomes in Clinical 
Trial Protocols: The SPIRIT-PRO Extension. JAMA 
2018;319:483-94.
7. Pe M, Dorme L, Coens C, et al. Statistical analysis of 
patient-reported outcome data in randomised controlled 
trials of locally advanced and metastatic breast cancer: a 
systematic review. Lancet Oncol 2018;19:e459-69.
8. U.S. Department of Health and Human Services 
FDA Center for Drug Evaluation and Research; U.S. 
Department of Health and Human Services FDA Center 
for Biologics Evaluation and Research; U.S. Department 
of Health and Human Services FDA Center for Devices 
and Radiological Health. Guidance for industry: patient-
reported outcome measures: use in medical product 
development to support labeling claims: draft guidance. 
Health Qual Life Outcomes 2006;4:79.
9. Bottomley A, Pe M, Sloan J, et al. Analysing data from 
patient-reported outcome and quality of life endpoints 
for cancer clinical trials: a start in setting international 
standards. Lancet Oncol 2016;17:e510-4.
10. Sprangers MA, Cull A, Bjordal K, et al. The European 
Organization for Research and Treatment of Cancer. 
Approach to quality of life assessment: guidelines for 
developing questionnaire modules. EORTC Study Group 
on Quality of Life. Qual Life Res 1993;2:287-95.
11. Juniper EF. Validated questionnaires should not be 
modified. Eur Respir J 2009;34:1015-7.
12. Pompili C, Brunelli A, Xiume F, et al. Prospective external 
convergence evaluation of two different quality-of-life 
instruments in lung resection patients. Eur J Cardiothorac 
Surg 2011;40:99-105.
13. Kuenstner S, Langelotz C, Budach V, et al. The 
comparability of quality of life scores. a multitrait 
multimethod analysis of the EORTC QLQ-C30, SF-36 
and FLIC questionnaires. Eur J Cancer 2002;38:339-48.
14. Apolone G, Filiberti A, Cifani S, et al. Evaluation of the 
EORTC QLQ-C30 questionnaire: a comparison with 
SF-36 Health Survey in a cohort of Italian long-survival 
cancer patients. Ann Oncol 1998;9:549-57.
15. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-
form health survey (SF-36). I. Conceptual framework and 
item selection. Med Care 1992;30:473-83.
16. Pompili C, Brunelli A. Quality of life after lung resection 
is not associated with functional objective measures. Eur 
Respir J 2013;42:283-5.
17. Brunelli A, Socci L, Refai M, et al. Quality of Life Before 
and After Major Lung Resection for Lung Cancer: A 
Prospective Follow-Up Analysis. Ann Thorac Surg 
2007;84:410-6.
18. Handy JJR, Asaph JW, Douville EC, et al. Does video-
assisted thoracoscopic lobectomy for lung cancer provide 
improved functional outcomes compared with open 
lobectomy? Eur J Cardiothorac Surg 2010;37:451-5.
19. Moller A, Sartipy U. Associations between changes in 
quality of life and survival after lung cancer surgery. J 
Thorac Oncol 2012;7:183-7.
20. Rizk NP, Ghanie A, Hsu M, et al. A Prospective Trial 
Comparing Pain and Quality of Life Measures After 
Anatomic Lung Resection Using Thoracoscopy or 
Thoracotomy. Ann Thorac Surg 2014;98:1160-6.
21. EuroQol Group. EuroQol--a new facility for the 
measurement of health-related quality of life. Health 
Policy 1990;16:199-208.
22. EuroQol Research Foundation. EQ-5D-5L User Guide, 
2019. Available online: https://euroqol.org/publications/
user-guides
23. Devlin NJ, Brooks R. EQ-5D and the EuroQol Group: 
Past, Present and Future. Appl Health Econ Health Policy 
2017;15:127-37.
24. Johnson JA, Pickard AS. Comparison of the EQ-5D and 
SF-12 health surveys in a general population survey in 
Alberta, Canada. Med Care 2000;38:115-21.
25. Koide R, Kikuchi A, Miyajima M, et al. Quality assessment 
using EQ-5D-5L after lung surgery for non-small cell 
lung cancer (NSCLC) patients. Gen Thorac Cardiovasc 
Surg 2019;67:1056-61.
26. Bejjani J, Fiore JF Jr, Lee L, et al. Validity of the 
EuroQol-5 dimensions as a measure of recovery after 
pulmonary resection. J Surg Res 2015;194:281-8.
27. Aaronson NK, Ahmedzai S, Bergman B, et al. The 
European Organization for Research and Treatment of 
Cancer QLQ-C30: a quality-of-life instrument for use in 
international clinical trials in oncology. J Natl Cancer Inst 
6900 Pompili et al. QoL questionnaires in lung surgery
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2020;12(11):6892-6901 | http://dx.doi.org/10.21037/jtd.2019.12.131
1993;85:365-76.
28. Osoba D, Zee B, Pater J, et al. Psychometric properties 
and responsiveness of the EORTC quality of Life 
Questionnaire (QLQ-C30) in patients with breast, ovarian 
and lung cancer. Qual Life Res 1994;3:353-64.
29. Nicklasson M, Bergman B. Validity, reliability and clinical 
relevance of EORTC QLQ-C30 and LC13 in patients 
with chest malignancies in a palliative setting. Qual Life 
Res 2007;16:1019-28.
30. Pompili C, Velikova G, White J, et al. Poor preoperative 
patient-reported quality of life is associated with 
complications following pulmonary lobectomy for lung 
cancer†. Eur J Cardiothorac Surg 2017;51:526-31.
31. Balduyck B, Hendriks J, Lauwers P, et al. Quality of life 
evolution after lung cancer surgery: A prospective study in 
100 patients. Lung Cancer 2007;56:423-31.
32. Schulte T, Schniewind B, Walter J, et al. Age-related 
impairment of quality of life after lung resection for non-
small cell lung cancer. Lung Cancer 2010;68:115-20.
33. Burfeind WR Jr, Tong BC, O'Branski E, et al. Quality of 
life outcomes are equivalent after lobectomy in the elderly. 
J Thorac Cardiovasc Surg 2008;136:597-604.
34. Bendixen M, Jørgensen OD, Kronborg C, et al. 
Postoperative pain and quality of life after lobectomy 
via video-assisted thoracoscopic surgery or anterolateral 
thoracotomy for early stage lung cancer: a randomised 
controlled trial. Lancet Oncol 2016;17:836-44.
35. Pompili C, Koller M, Velikova G, et al. EORTC QLQ-C30 
summary score reliably detects changes in QoL three 
months after anatomic lung resection for Non-Small Cell 
Lung Cancer (NSCLC). Lung Cancer 2018;123:149-54.
36. Giesinger JM, Kieffer JM, Fayers PM, et al. Replication 
and validation of higher order models demonstrated that 
a summary score for the EORTC QLQ-C30 is robust. J 
Clin Epidemiol 2016;69:79-88.
37. Bergman B, Aaronson NK, Ahmedzai S, et al. The 
EORTC QLQ-LC13: a modular supplement to the 
EORTC Core Quality of Life Questionnaire (QLQ-C30) 
for use in lung cancer clinical trials. EORTC Study Group 
on Quality of Life. Eur J Cancer 1994;30A:635-42.
38. Cella DF, Tulsky DS, Gray G, et al. The Functional 
Assessment of Cancer Therapy scale: development 
and validation of the general measure. J Clin Oncol 
1993;11:570-9.
39. Webster K, Cella D, Yost K. The Functional Assessment of 
Chronic Illness Therapy (FACIT) Measurement System: 
properties, applications, and interpretation. Health Qual 
Life Outcomes 2003;1:79.
40. Cella DF, Bonomi AE, Lloyd SR, et al. Reliability and 
validity of the Functional Assessment of Cancer Therapy-
Lung (FACT-L) quality of life instrument. Lung Cancer 
1995;12:199-220.
41. Cella D, Eton DT, Fairclough DL, et al. What is a 
clinically meaningful change on the Functional Assessment 
of Cancer Therapy-Lung (FACT-L) Questionnaire? 
Results from Eastern Cooperative Oncology Group 
(ECOG) Study 5592. J Clin Epidemiol 2002;55:285-95.
42. Luckett T, King MT, Butow PN, et al. Choosing between 
the EORTC QLQ-C30 and FACT-G for measuring 
health-related quality of life in cancer clinical research: 
issues, evidence and recommendations. Ann Oncol 
2011;22:2179-90.
43. Ring AE, Cheong KA, Watkins CL, et al. A Randomized 
Study of Electronic Diary versus Paper and Pencil 
Collection of Patient-Reported Outcomes in Patients with 
Non-Small Cell Lung Cancer. Patient 2008;1:105-13.
44. Porter LS, Keefe FJ, Garst J, et al. Self-efficacy for 
managing pain, symptoms, and function in patients with 
lung cancer and their informal caregivers: associations with 
symptoms and distress. Pain 2008;137:306-15.
45. Videtic GMM, Reddy CA, Sorenson L. A prospective 
study of quality of life including fatigue and pulmonary 
function after stereotactic body radiotherapy for medically 
inoperable early-stage lung cancer. Support Care Cancer 
2013;21:211-8.
46. Hollen PJ, Gralla RJ, Kris MG, et al. Quality of life 
assessment in individuals with lung cancer: testing the 
Lung Cancer Symptom Scale (LCSS). Eur J Cancer 
1993;29A Suppl 1:S51-8.
47. Hollen PJ, Gralla RJ, Kris MG, et al. A comparison of 
visual analogue and numerical rating scale formats for the 
Lung Cancer Symptom Scale (LCSS): does format affect 
patient ratings of symptoms and quality of life? Qual Life 
Res 2005;14:837-47.
48. Ferrero C, Badellino S, Filippi AR, et al. Pulmonary 
function and quality of life after VMAT-based stereotactic 
ablative radiotherapy for early stage inoperable NSCLC: a 
prospective study. Lung Cancer 2015;89:350-6.
49. Koller M, Warncke S, Hjermstad MJ, et al. Use of 
the lung cancer-specific Quality of Life Questionnaire 
EORTC QLQ-LC13 in clinical trials: A systematic review 
of the literature 20 years after its development. Cancer 
2015;121:4300-23.
50. Koller M, Hjermstad MJ, Tomaszewski KA, et al. An 
international study to revise the EORTC questionnaire for 
assessing quality of life in lung cancer patients. Ann Oncol 
6901Journal of Thoracic Disease, Vol 12, No 11 November 2020
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2020;12(11):6892-6901 | http://dx.doi.org/10.21037/jtd.2019.12.131
2017;28:2874-81.
51. 26th Annual Conference of the International Society for 
Quality of Life Research. Qual Life Res 2019;28:1-190.
52. Kuliś D BA, Whittaker C, van de Poll-Franse LV, et al. 
The Use of the EORTC Item Library to Supplement 
EORTC Quality of Life Instruments. The International 
Society for Pharmacoeconomics and Outcomes Research 
(ISPOR) 20th Annual European Congress; 2017 Nov 4-8; 
Glasgow, Scotland. 2017.
53. Basch E, Abernethy AP, Mullins CD, et al. 
Recommendations for incorporating patient-reported 
outcomes into clinical comparative effectiveness research 
in adult oncology. J Clin Oncol 2012;30:4249-55.
54. Garcia SF, Cella D, Clauser SB, et al. Standardizing patient-
reported outcomes assessment in cancer clinical trials: 
a patient-reported outcomes measurement information 
system initiative. J Clin Oncol 2007;25:5106-12.
55. Jones RS, Stukenborg GJ. Patient-Reported Outcomes 
Measurement Information System (PROMIS) Use 
in Surgical Care: A Scoping Study. J Am Coll Surg 
2017;224:245-254.e1.
56. Weinberger M, Oddone EZ, Samsa GP, et al. Are health-
related quality-of-life measures affected by the mode of 
administration? J Clin Epidemiol 1996;49:135-40.
57. Gundy CM, Aaronson NK. Effects of mode of 
administration (MOA) on the measurement properties of 
the EORTC QLQ-C30: a randomized study. Health Qual 
Life Outcomes 2010;8:35.
58. Velikova G, Brown JM, Smith AB, et al. Computer-based 
quality of life questionnaires may contribute to doctor-
patient interactions in oncology. Br J Cancer 2002;86:51-9.
59. Basch E, Deal AM, Kris MG, et al. Symptom Monitoring 
With Patient-Reported Outcomes During Routine Cancer 
Treatment: A Randomized Controlled Trial. J Clin Oncol 
2016;34:557-65.
60. Pompili C, Franks KN, Brunelli A, et al. Patient reported 
outcomes following video assisted thoracoscopic (VATS) 
resection or stereotactic ablative body radiotherapy (SABR) 
for treatment of non-small cell lung cancer: protocol 
for an observational pilot study (LiLAC). J Thorac Dis 
2017;9:2703-13.
61. Khullar OV, Rajaei MH, Force SD, et al. Pilot Study to 
Integrate Patient Reported Outcomes After Lung Cancer 
Operations Into The Society of Thoracic Surgeons 
Database. Ann Thorac Surg 2017;104:245-53.
62. Denis F, Basch E, Septans AL, et al. Two-Year Survival 
Comparing Web-Based Symptom Monitoring vs Routine 
Surveillance Following Treatment for Lung Cancer. JAMA 
2019;321:306-7.
63. Avery KNL, Richards HS, Portal A, et al. Developing 
a real-time electronic symptom monitoring system for 
patients after discharge following cancer-related surgery. 
BMC Cancer 2019;19:463.
Cite this article as: Pompili C, Koller M, Velikova G. 
Choosing the right survey: the lung cancer surgery. J Thorac 
Dis 2020;12(11):6892-6901. doi: 10.21037/jtd.2019.12.131
